BOOK
Cardiovascular Emergencies, An Issue of Emergency Medicine Clinics of North America, E-Book
(2015)
Additional Information
Book Details
Abstract
Drs. Tewelde and Reynolds have put together an excellent issue on Cardiovascuar Emergencies. Articles include:Pregnancy Related Coronary Artery Disease, Decompensated Cyanotic Heart Disease, Blunt Cardiac Injury, Blunt Cardiac Injury, STEMI Chameleons, Hypertensive Emergency, Troubleshooting the Pacer/ICD, Cardiogenic Shock, Cardiac Arrest, and more!
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Cover | ||
Cardiovascular Emergencies\r | i | ||
Copyright\r | ii | ||
Contributors | iii | ||
Contents | vii | ||
Emergency Medicine Clinics Of North America\r | xi | ||
Foreword\r | xv | ||
Preface\r | xvii | ||
Cardiovascular Catastrophes in the Obstetric Population | 483 | ||
Key points | 483 | ||
Introduction | 483 | ||
Hypertensive emergencies | 484 | ||
Acute coronary syndrome | 486 | ||
Cardiomyopathy | 490 | ||
Dysrhythmias | 491 | ||
Coronary Artery and Aortic Dissection | 492 | ||
Thromboembolism | 493 | ||
Cardiac arrest | 494 | ||
Summary | 495 | ||
References | 495 | ||
The Critically Ill Infant with Congenital Heart Disease | 501 | ||
Key points | 501 | ||
Introduction | 501 | ||
Epidemiology | 503 | ||
Screening | 503 | ||
Cyanosis | 504 | ||
Presentation | 505 | ||
Diagnosis | 505 | ||
Hyperoxia Test | 507 | ||
Physical Examination | 507 | ||
Electrocardiography | 508 | ||
Voltage criteria for hypertrophy | 509 | ||
Laboratory analysis | 509 | ||
Imaging | 509 | ||
Echocardiography | 510 | ||
Emergency department evaluation | 510 | ||
Medical Management | 512 | ||
Special considerations | 514 | ||
Summary | 515 | ||
References | 516 | ||
Blunt Cardiac Injury | 519 | ||
Key points | 519 | ||
Epidemiology | 519 | ||
Mechanisms and injury patterns | 520 | ||
Cardiac Concussion (Also Called Cardiac Contusion) | 520 | ||
Commotio Cordis | 521 | ||
Cardiac Rupture | 521 | ||
Valvular Injury | 521 | ||
Coronary Artery Injury | 522 | ||
Pericardial Injury | 522 | ||
Dysrhythmias | 522 | ||
Diagnosis | 522 | ||
Treatment | 524 | ||
Summary | 525 | ||
References | 525 | ||
Chameleons | 529 | ||
Key points | 529 | ||
Introduction | 529 | ||
Left ventricular hypertrophy | 530 | ||
Early repolarization | 531 | ||
Left bundle branch block | 532 | ||
Myopericarditis | 532 | ||
Brugada syndrome | 533 | ||
Prominent T waves | 533 | ||
Hyperkalemia | 534 | ||
Early Repolarization | 534 | ||
Takotsubo or stress-related ST-segment elevation | 534 | ||
Ventricular aneurysm | 535 | ||
Summary | 535 | ||
References | 535 | ||
Hypertensive Emergencies in the Emergency Department | 539 | ||
Key points | 539 | ||
Introduction | 539 | ||
Definition | 540 | ||
Evaluation | 541 | ||
History | 541 | ||
Physical Examination | 542 | ||
Diagnostic Testing | 543 | ||
Management of hypertensive emergencies | 543 | ||
Hypertensive Encephalopathy | 543 | ||
Pulmonary Edema | 544 | ||
Myocardial Ischemia | 545 | ||
Aortic Dissection | 545 | ||
Acute Renal Failure | 548 | ||
Sympathomimetic Crisis | 548 | ||
Hypertensive Emergency in Pregnancy | 548 | ||
Summary | 549 | ||
References | 549 | ||
Congestive Heart Failure | 553 | ||
Key points | 553 | ||
Introduction | 553 | ||
Pathophysiology | 554 | ||
Classification | 554 | ||
Causes | 555 | ||
Symptoms and signs | 555 | ||
Diagnostic testing | 555 | ||
Electrocardiogram | 555 | ||
Chest Radiography | 555 | ||
Echocardiography | 556 | ||
Laboratory Testing | 556 | ||
Emergency department treatment | 557 | ||
Noninvasive Positive-Pressure Ventilation | 558 | ||
Pharmacologic Therapy | 558 | ||
Mechanical Assistance | 560 | ||
Summary | 560 | ||
References | 561 | ||
Cardiotoxicodynamics | 563 | ||
Key points | 563 | ||
Basic cardiac electrophysiology | 563 | ||
Ion Channels and the Myocardial Cell Action Potential | 563 | ||
Cardiac Dysrhythmia Initiation and Propagation | 564 | ||
Antidysrhythmics | 566 | ||
Introduction | 566 | ||
Pathophysiology | 567 | ||
Clinical Effects | 568 | ||
Sodium channel blockers | 568 | ||
Potassium channel blockers | 569 | ||
Management | 569 | ||
β-blockers and calcium channel blockers | 572 | ||
Background | 572 | ||
Pathophysiology | 573 | ||
β-blockers | 573 | ||
Calcium channel blockers | 573 | ||
Clinical Effects | 574 | ||
Cardiovascular | 574 | ||
Central nervous system | 575 | ||
Endocrine | 575 | ||
Final common pathway | 575 | ||
Management | 575 | ||
Cardioactive steroids | 578 | ||
Introduction | 578 | ||
Pathophysiology | 578 | ||
Clinical manifestations | 578 | ||
Overview | 578 | ||
Acute toxicity | 579 | ||
Chronic toxicity | 579 | ||
Diagnostics | 579 | ||
Management | 581 | ||
Gastrointestinal decontamination | 581 | ||
Fluid and electrolyte therapy | 581 | ||
Volume depletion | 581 | ||
Advanced management | 581 | ||
β-agonists and methylxanthines | 582 | ||
Background | 582 | ||
Pathophysiology | 583 | ||
Clinical Manifestations | 584 | ||
Cardiovascular | 584 | ||
Central nervous system | 585 | ||
Gastrointestinal | 585 | ||
Metabolic | 585 | ||
Management | 585 | ||
Central α2-agonists | 587 | ||
Introduction | 587 | ||
Pathophysiology | 587 | ||
Clinical Manifestations | 589 | ||
Special considerations | 589 | ||
Management | 589 | ||
Acknowledgments | 590 | ||
References | 590 | ||
Atrial Fibrillation | 597 | ||
Key points | 597 | ||
Overview | 597 | ||
Causes | 598 | ||
Diagnosis | 599 | ||
Management | 599 | ||
Rate Control | 600 | ||
Rhythm Control | 601 | ||
Anticoagulation | 604 | ||
Vitamin K antagonists | 606 | ||
Direct thrombin inhibitors | 606 | ||
Factor Xa inhibitors | 606 | ||
Antiplatelet therapy | 607 | ||
Human Immunodeficiency Virus Infection–Related Heart Disease | 613 | ||
Key points | 613 | ||
Introduction | 613 | ||
Definitions | 614 | ||
Coronary artery disease and acute coronary syndrome | 614 | ||
Arrhythmias | 616 | ||
Myocarditis and cardiomyopathy | 617 | ||
Pericardial effusion | 618 | ||
Valvular disease | 619 | ||
Summary | 619 | ||
References | 620 | ||
Management of Crashing Patients with Pulmonary Hypertension | 623 | ||
Key points | 623 | ||
Introduction | 623 | ||
Classification | 624 | ||
Right ventricular dysfunction | 626 | ||
Emergency department presentation | 627 | ||
Diagnostic studies | 628 | ||
Laboratory Testing | 628 | ||
Electrocardiogram | 628 | ||
Chest Radiography | 629 | ||
Computed Tomography | 629 | ||
Echocardiography | 629 | ||
Initial management | 632 | ||
Preload and Volume Status | 632 | ||
Optimize Right Ventricular Systolic Function | 633 | ||
Maintain Right Coronary Artery Perfusion | 634 | ||
Reduce Right Ventricular Afterload | 634 | ||
Nitric oxide | 635 | ||
Prostanoids | 635 | ||
Phosphodiesterase inhibitors | 636 | ||
Additional considerations | 636 | ||
Dysrhythmias | 636 | ||
Anemia | 636 | ||
Anticoagulation | 636 | ||
Mechanical Circulatory Support | 637 | ||
Summary | 637 | ||
Acknowledgments | 637 | ||
References | 637 | ||
Cardiogenic Shock | 645 | ||
Key points | 645 | ||
Introduction | 645 | ||
Pathophysiology | 646 | ||
Treatment strategies | 647 | ||
Medical management | 647 | ||
Digitalis | 647 | ||
Adrenergics | 647 | ||
Phosphodiesterase Inhibitors | 648 | ||
Calcium Sensitizers | 648 | ||
Other Considerations | 648 | ||
Mechanical support | 648 | ||
Intra-aortic Balloon Pump | 649 | ||
Ventricular-Assist Device | 649 | ||
Extracorporeal Membrane Oxygenation | 649 | ||
Summary | 650 | ||
References | 650 | ||
Emergency Care of Patients with Pacemakers and Defibrillators | 653 | ||
Key points | 653 | ||
Introduction | 653 | ||
Permanent pacemakers | 654 | ||
Indications for pacemaker placement | 654 | ||
Pacemaker malfunction | 655 | ||
Failure to Pace | 656 | ||
Failure to Capture | 656 | ||
Failure to Sense: Oversensing and Undersensing | 656 | ||
Components of the pacemaker | 656 | ||
Pulse Generator | 657 | ||
Pacemaker Leads | 657 | ||
Pacemaker Lead/Myocardium Interface | 657 | ||
Emergency department approach to pacemaker malfunction | 658 | ||
Investigation and Work-up | 658 | ||
Management | 658 | ||
Pacemaker-induced dysrhythmias and syndromes | 659 | ||
Pacemaker-mediated Tachycardia | 659 | ||
Runaway Pacemaker | 659 | ||
Pacemaker Syndrome | 660 | ||
Advanced cardiac life support | 660 | ||
Implantable cardioverter-defibrillators | 660 | ||
Indications for implantable cardioverter-defibrillators | 660 | ||
Approach to the implantable cardioverter-defibrillator that has fired a single time | 661 | ||
Approach to the implantable cardioverter-defibrillator that has fired multiple times | 661 | ||
Inappropriate Shocks | 662 | ||
Appropriate Shocks | 662 | ||
Electrical Storm | 662 | ||
Treatment | 662 | ||
Checking cardiac biomarkers after defibrillation | 663 | ||
Cardiac arrest in patients with implantable cardioverter-defibrillators | 663 | ||
Pad Placement | 663 | ||
Chest Compressions | 663 | ||
Use of Magnets | 663 | ||
Complications associated with device insertion: pacemakers and implantable cardioverter-defibrillators | 663 | ||
Pocket Hematoma | 663 | ||
Pocket Infections | 664 | ||
Lead Infections | 664 | ||
Pericardial Effusion | 664 | ||
Pneumothorax | 664 | ||
Thrombosis/Superior Vena Cava Syndrome | 664 | ||
Summary | 665 | ||
References | 665 | ||
Cardiac Arrest Resuscitation | 669 | ||
Key points | 669 | ||
Introduction | 669 | ||
General management considerations | 670 | ||
Pit Crew Cardiopulmonary Resuscitation | 670 | ||
Circulatory support | 671 | ||
Mechanical Cardiopulmonary Resuscitation | 671 | ||
Compression-Only Cardiopulmonary Resuscitation | 671 | ||
Continuous Versus 30:2 | 672 | ||
Defibrillation | 672 | ||
Energy Selection and Delivery Method | 672 | ||
Timing of Shock Delivery | 673 | ||
The Peri-Shock Pause | 673 | ||
Airway | 674 | ||
Adjuncts | 674 | ||
Cricoid Pressure | 674 | ||
Advanced Airways | 674 | ||
Oxygenation | 675 | ||
Ventilation | 676 | ||
Pharmacotherapy | 676 | ||
Advanced Cardiac Life Support Drugs: General Principles | 676 | ||
Epinephrine | 676 | ||
Vasopressin | 677 | ||
Atropine | 677 | ||
Antiarrhythmics (Amiodarone or Lidocaine) | 677 | ||
Devices | 678 | ||
Mechanical Chest Compression Devices | 678 | ||
Active Chest Compression-Decompression | 678 | ||
Impedance Threshold Device | 678 | ||
A universal termination of resuscitation rule | 678 | ||
Novel future directions | 678 | ||
Dispatching Lay Rescuers Via Short Message Service (SMS) Mobile Phone Messages | 679 | ||
Geographic Mapping of Automated External Defibrillators | 679 | ||
Extracorporeal Life Support | 679 | ||
References | 680 | ||
Appendix | 690 | ||
Postcardiac Arrest Management | 691 | ||
Key points | 691 | ||
Overview and goals of care | 691 | ||
Determining the cause and extent of injury after cardiac arrest | 691 | ||
History and Physical Examination | 691 | ||
Baseline Neurologic Examination | 692 | ||
Diagnostic Testing | 692 | ||
Electrocardiogram | 692 | ||
Laboratory testing | 694 | ||
Imaging | 694 | ||
Postcardiac Arrest Illness Severity | 695 | ||
Management of the postarrest patient | 695 | ||
Minimize Ongoing Brain Injury | 696 | ||
Neurologic Prognostication | 697 | ||
Airway | 697 | ||
Oxygenation | 698 | ||
Ventilation | 698 | ||
Hemodynamic Considerations: End-Organ Perfusion | 698 | ||
Myocardial Dysfunction | 699 | ||
Coronary Revascularization | 699 | ||
Temperature Management | 700 | ||
Indications and Contraindications | 700 | ||
Timing, Goal, and Duration | 700 | ||
Methods for Induction/Maintenance | 701 | ||
Sedation and Shivering | 702 | ||
Rewarming | 702 | ||
Side Effects | 702 | ||
General Clinical Care | 703 | ||
Regionalization of care | 703 | ||
Summary | 705 | ||
References | 705 | ||
Appendix | 712 | ||
Index | 713 |